If you get colon cancer, your prognosis depends partly on where it started

Hepatitis C May Increase Risk for Head and Neck Cancer
June 6, 2016
Novel Multiple Myeloma Regimen Slows Disease Progression
June 7, 2016
Show all

If you get colon cancer, your prognosis depends partly on where it started

Whether your colon cancer started on the left side or the ride side could affect your chances of survival.

People with cancer that starts on the left side of their colon live significantly longer than those with right-side tumors, according to a new study that provides insights into how best to match drugs to patients with advanced disease.

The retrospective analysis, released Wednesday, involved a federally funded clinical trial with more than 1,100 colon-cancer patients. Overall, it found that those with left-side tumors survived for a median of 33.3  months, while those with right-side tumors survived for 19.4 months.

Lead author Alan Venook, a professor of medicine at the University of California at San Francisco, said previous studies had suggested tumor location played a role in patients’ survival, but the effect shown by the new study was greater than he expected.

The data also turned up a striking difference in drug efficacy depending on the location of the tumors. Two therapies were used in the trial, in combination with chemotherapy, to see whether one worked better than the other. The answer was no, based on initial results.

But when the data was evaluated based on a tumor’s location, things changed. Avastin was associated with longer survival times in cases of right-side tumors, while Erbitux was linked to longer survival with left-side malignancies.

Read Full Article: If you get colon cancer, your prognosis depends partly on where it started – The Washington Post

Read Full Article: If you get colon cancer, your prognosis depends partly on where it started – The Washington Post

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.